36 results
S-8
EX-99.1
NGNE
Neurogene Inc
20 Feb 24
Registration of securities for employees
4:16pm
, death, retirement, authorized leave of absence or any other change or purported change in a Participant’s Service Provider status and the extent
8-K
EX-10.23
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
Retirement Income Security Act of 1974 (“ERISA”), the Family and Medical Leave Act, the Fair Credit Reporting Act, the Occupational Safety and Health Act
8-K
EX-10.24
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
Act of 1990 (“OWBPA”), Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Employee Retirement Income Security Act
8-K
EX-3.3
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
in the authorized number of directors and any vacancies in the Board of Directors resulting from death, resignation, retirement, disqualification, removal
S-4/A
0uniyaanz1s8avrv0qr
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4
c8zqkoh3ite6mhzr50pn
18 Aug 23
Registration of securities issued in business combination transactions
6:19pm
425
k7u p462o8
18 Jul 23
Business combination disclosure
8:37am
8-K
EX-2.1
n7g 8eqzuici
18 Jul 23
Neurogene and Neoleukin Announce Definitive Merger Agreement
8:34am
8-K
EX-1.1
io4l8lfbmo1bbmwy5g
4 Nov 21
Entry into a Material Definitive Agreement
4:58pm
8-K
EX-10.1
widiipqlozhlqjwsj
14 May 21
Submission of Matters to a Vote of Security Holders
8:09am
8-K
EX-1.1
7qqlv9it6n
2 Jul 20
Announces Pricing of $76.2 Million Public Offering
4:09pm
424B5
hfkr4fvzjrwtrkq 1t
2 Jul 20
Prospectus supplement for primary offering
4:06pm